ModifiedColorado Rocky Mountain Health PlansPolicy CS054.W

Airway Clearance Devices — High-frequency chest wall oscillation (HFCWO) systems

This policy governs medical necessity, coverage, and rental trial requirements for high-frequency chest wall oscillation (HFCWO) and related airway clearance devices for Colorado Rocky Mountain Health Plans members (state-specific exceptions listed). It addresses indications, excluded uses, and applicable billing codes.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyAirway Clearance Devices — HFCWO

Policy CodePolicy CS054.W

Change TypeCriteria updatedocumentation requirements added/removed

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionObtain and submit medical records documenting the initial 2-month rental trial results, specific device requested, recent imaging/diagnostics, comorbidities, and evidence of proper use for continuation requests.

SourceLink

POLICY UPDATE CHANGES

Updated medical necessity clinical coverage criteria for a high-frequency chest wall oscillation (HFCWO) system and replaced InterQual reference with updated InterQual Airway or Secretion Clearance Devices (Custom) - UHG.

Added required medical record documentation items including specific device requested, trial vs ongoing request, results of recent imaging/diagnostics, comorbidities, and for continuation beyond two-month trial include evidence of proper use.

Removed requirement for current physician prescription and CT scan report confirming bronchiectasis diagnosis (if applicable) from the documentation list.

Replaced wording about failed standard treatments to 'treatments tried, failed, or contraindicated ... include the dates, duration, and reason for discontinuation.'

Removed content/language pertaining to the state of Louisiana.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information and archived previous policy version CS054.V.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Initial Coverage Criteria (HFCWO)

Covered when ALL of the following are met

Primary Criteria: An initial 2-month rental trial of an HFCWO system is performed and demonstrates individual tolerance and clinical benefit2-month rental trial

Required before ongoing medical necessity determination via InterQual Airway or Secretion Clearance Devices (Custom) - UHG

Covered Indications: Member has one of the following diagnoses: neuromuscular disease, bronchiectasis, or cystic fibrosis

HFCWO is considered proven and medically necessary for these conditions

Not Medically Necessary / Unproven

Not covered / not medically necessary

Excluded Indications: Use of HFCWO for any condition other than neuromuscular disease, bronchiectasis, or cystic fibrosis

Considered unproven and not medically necessary due to insufficient evidence

Devices Considered Unproven: Intrapulmonary percussive ventilation devices for home use and combination continuous PEP/continuous high-frequency oscillation/nebulized medication therapy devices (OLE)

These devices are considered unproven and not medically necessary

OLE — Not Medically Necessary

Coverage stance for combination OLE devices

OLE not covered: Combination continuous positive expiratory pressure, continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary due to insufficient quality evidence or consistency of findings

Explicit determination from policy text

HFCWO and alternative ACTs — Mixed evidence

Coverage considerations for HFCWO and other ACTs

Evidence summary - mixed quality: Systematic reviews and RCTs report variable and often low-to-very-low certainty evidence; most comparisons show little or no difference in lung function outcomes between HFCWO (or other oscillatory chest physical therapies) and alternative ACTs, though individual studies report differences in secondary outcomes or exacerbation rates

Use clinical judgment; consider individual response, preference, and training in ACTs

Clinical approach: Because no single ACT is consistently superior, clinicians may trial alternative ACTs (e.g., PEP, ACBT, autogenic drainage, MI-E where indicated) and select therapy based on individual response, adherence, and preferences

NICE and other reviews recommend individualized assessment and training

Evidence and guideline-based coverage considerations

Summary of clinical coverage-relevant conclusions and guideline positions

IPV evidence status: Evidence for intrapulmonary percussive ventilation (IPV) is limited and inconsistent; systematic reviews and small RCTs provide weak or variable support for benefits and further adequately powered trials are needed before routine home use is supported

Hassan et al. (2021a) and Reychler et al. (2018) concluded evidence is weak or insufficient

OLE perioperative data: A prospective multicenter study reported reduced postoperative pulmonary complications, ventilator hours, and hospital length of stay with OLE in high-risk surgical patients, but authors call for controlled trials to confirm safety and efficacy

Single multicenter study suggests benefit but not definitive

Neuromuscular disease guideline indicators: Guidelines (ATS, BTS) recommend assisted cough technologies and aggressive airway clearance strategies for patients with neuromuscular weakness; consider assisted cough when PCF < 270 L/min or MEP < 60 cm H2O<270 L/min (PCF); <60 cm H2O (MEP)

Combination continuous positive expiratory pressure (PEP), continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary. The policy states these combination OLE systems lack sufficient quality evidence or consistent findings to support routine coverage, and therefore requests for these devices should be treated as not medically necessary.

Combination OLE devices (continuous PEP + continuous high-frequency oscillation + nebulized medication therapy) are explicitly excluded as not medically necessary. The policy determination reflects insufficient evidence and inconsistent findings for these combination devices and directs that such devices are not covered.

Routine long-term home use of intrapulmonary percussive ventilation (IPV) is not supported by sufficient high-quality evidence or consistent findings. Systematic reviews and randomized trials report weak or mixed results—some short-term physiologic benefits have been observed in select settings, but overall the evidence is insufficient to support routine home coverage for IPV.

Policy language related to the state of Louisiana has been removed in this revision. The Policy History documents that content/language pertaining to Louisiana was deleted as part of the template and coverage updates.

High-frequency chest wall oscillation (HFCWO) is considered medically necessary only for specific conditions (neuromuscular disease, bronchiectasis, and cystic fibrosis) when criteria are met; for other indications HFCWO is unproven and not medically necessary. Additionally, HFCWO is not supported for broader indications and combination therapies (such as OLE) are separately determined to be unproven.

Combination devices that merge continuous PEP, continuous high-frequency oscillation, and nebulized medication delivery for oscillation and lung expansion are regarded as unproven and therefore not medically necessary. Requests involving these combined systems should be denied unless robust evidence demonstrating clinical benefit is provided.

For cystic fibrosis, the policy notes that evidence shows HFCWO is not as effective as other airway clearance techniques; NICE specifically advises not offering HFCWO for people with cystic fibrosis except in exceptional clinical circumstances determined by the specialist team. Use of HFCWO in CF should therefore be limited to cases with specialist justification.

Coding

Applicable HCPCS/Procedure CodesHCPCS

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter).
A7025	High frequency chest wall oscillation system vest, replacement for use with patient- owned equipment, each.
A7026	High frequency chest wall oscillation system hose, replacement for use with patient- owned equipment, each.
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device.
E0481	Intrapulmonary percussive ventilation system and related accessories.
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each

Applicable ICD-10 Diagnosis Codes (sample list)ICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated.
B91	Sequelae of poliomyelitis.
E74.02	Pompe disease.
E84.0	Cystic fibrosis with pulmonary manifestations.
G12.21	Amyotrophic lateral sclerosis.
G71.3	Mitochondrial myopathy, not elsewhere classified.
J47.9	Bronchiectasis, uncomplicated
Z99.11	Dependence on respirator [ventilator] status

Provider Actions and Prior Authorization

Prior Authorization

Initial 2-Month Rental Trial Requirement

For all indications for an HFCWO system, an initial 2-month rental trial must be performed and documented prior to approval of ongoing use to confirm individual tolerance and efficacy.

Apply rental-trial requirement to initial requests for HFCWO systems (2 months).
Documentation must indicate whether the request is for an initial trial or ongoing use.

Denial Risk

Prior authorization implication for OLE

Combination continuous positive expiratory pressure (continuous PEP), continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary. Such devices require prior authorization but will be denied as not medically necessary when requested for OLE therapy.

Medical Necessity

DME Medical Necessity

Medical necessity for ongoing HFCWO requires:

DME Necessity: Member has neuromuscular disease, bronchiectasis, or cystic fibrosis AND an initial 2-month rental trial demonstrates tolerance and clinical benefit (e.g., reduced exacerbations, decreased hospitalizations, or measurable functional improvement)2-month trial

Ongoing use is evaluated using InterQual Airway or Secretion Clearance Devices (Custom) - UHG and supported by clinical documentation

HFCWO — Supportive but limited evidence

Evidence-based considerations for HFCWO use

Supportive but limited evidence: Cohort and observational studies suggest HFCWO may reduce hospitalizations, total medical costs, and hospitalization days in select neurologically impaired pediatric and neuromuscular populations, but findings are limited by lack of concurrent controls and potential confounding

Rental & Purchase Rules

Equipment / HCPCS	Rule
E0483 — High frequency chest wall oscillation system (includes accessories and supplies)
E0469 — Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
Policy rule: Initial provision via a 2-month rental trial — required to confirm individual tolerance and efficacy before ongoing medical necessity determination (ongoing use evaluated per InterQual criteria)

Device / Topic	Notes
High-frequency chest wall compression (HFCWC/HFCWO) devices (FDA product code BYI)
Informational: designed to promote airway clearance and improve bronchial drainage; refer to FDA PMN database (product code BYI) for device-specific details
Applicable HCPCS listed for reference (includes E0483, E0469, E0481; replacement/accessory codes A7021, A7025, A7026). Inclusion of codes in policy is for reference and does not by itself guarantee coverage

Required Documentation

Documentation Required

Submit clinical records and 2-month trial outcomes for continuation requests

Provide clinical records documenting the member meets the clinical criteria and include documentation of the 2-month rental trial showing tolerance, adherence, and clinical response when seeking continuation of coverage.

Submit trial outcome documentation demonstrating clinical benefit
Include adherence and response data to support continuation

Documentation Required

Document device use, adherence, and clinical response

Include clinical notes that document device utilization details (frequency and duration), patient adherence, and observed clinical response to support authorization decisions and interpretation of outcomes.

Document how often and how long the device was used and any barriers to use
Record clinical signs of benefit or adverse effects

Background and Scope

When cough and mucociliary clearance are inadequate due to disease (for example, cystic fibrosis, neuromuscular disease, or bronchiectasis), HFCWO devices (vest systems driven by an air-pulse generator) provide external chest wall oscillation intended to mobilize secretions and support airway clearance. The policy recognizes HFCWO as a device-based airway clearance therapy with specific indications and rental trial requirements.

Definitions

Bronchiectasis — definition and clinical note

DefinitionBronchiectasis: a chronic respiratory disease characterized by airway dilation with recurrent, chronic, or refractory infections; clinically significant bronchiectasis has at least two of: cough most days, sputum production most days, or history of exacerbations; diagnosis confirmed radiographically by CT

Clinical noteBronchiectasis is associated with increased mucus retention and infection risk; airway clearance therapies (including consideration of HFCWO) are used when secretion clearance is inadequate

Radiographic confirmationPresence and classification confirmed by high-resolution, spiral, or standard computed tomography scan (per international consensus)

OLE — definition

DefinitionOLE: combination continuous positive expiratory pressure (PEP), continuous high-frequency oscillation, and nebulized medication therapy for oscillation and lung expansion

Not Covered / Exclusions

Not covered: HFCWO for indications other than neuromuscular disease, bronchiectasis, or cystic fibrosis (considered unproven); combination CPAP/oscillation/nebulization (OLE) devices; and intrapulmonary percussive ventilation (IPV) for long-term home use due to insufficient quality evidence. These exclusions reflect the policy's conclusion that evidence is inadequate to support routine coverage for these indications or device types.

Not covered: Combination CPAP/oscillation/nebulization (OLE) systems—these combination therapies are categorized as unproven and not medically necessary because current evidence is insufficient in quality and consistency to demonstrate clinical benefit for routine use.

Not covered: Long-term home use of intrapulmonary percussive ventilation (IPV) lacks sufficient quality evidence to support coverage. Systematic reviews and trials show weak, inconsistent, or setting-specific benefits and recommend further investigation before endorsing routine home use.

Not covered: HFCWO should not be routinely offered for people with cystic fibrosis; NICE guidance states it should only be used in exceptional clinical circumstances decided by the specialist CF team, reflecting limited evidence of superiority compared with other airway clearance techniques.

Not covered: Long-term home use of IPV is specifically listed as lacking sufficient high-quality evidence to support coverage. The policy cites systematic reviews and RCT data showing weak or inconsistent evidence and therefore excludes routine home IPV use from coverage.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyAirway Clearance Devices — HFCWO

Policy CodePolicy CS054.W

Change TypeCriteria updatedocumentation requirements added/removed

Effective DateMar 1, 2026

Next Review DateN/A

SourceLink

On This Page

Denial Risk

HFCWO restricted in cystic fibrosis

For people with cystic fibrosis, do not offer HFCWO as a routine airway clearance technique. HFCWO is restricted and considered not recommended except in exceptional clinical circumstances determined by the specialist cystic fibrosis team; such exceptions are subject to Individual Funding Request processes.

NICE: Do not offer HFCWO for cystic fibrosis except in exceptional clinical circumstances.
Specialist CF team must document rationale for exception; follow applicable funding request policies.

Documentation Required

Assessment documentation for neuromuscular disease

For members with neuromuscular disease, include guideline-recommended assessments to support medical necessity, such as vital capacity measurements and cough peak flow where applicable, and sleep-disordered breathing assessments per BTS guidance.

Measure and report vital capacity for members able to perform spirometry.
Report cough peak flow for children >12 years when assessing secretion clearance.
Provide sleep-disordered breathing assessment results when indicated (e.g., VC <60% predicted) and any relevant feeding/swallowing assessments.

Step Therapy

Therapy sequencing and technique preference

Therapy selection should be individualized. Evidence does not support a single airway clearance technique as universally superior; clinicians may trial alternative ACTs (e.g., PEP, ACBT, directed coughing) to identify the optimal approach and should document prior therapies tried, failed, or contraindicated.

Document prior airway clearance techniques attempted, dates, duration, and reason for discontinuation (tried, failed, or contraindicated).
NICE recommends assessing ability to clear mucus, training in ACTs, and regular reassessment; prefer other ACTs before HFCWO when clinically appropriate.

DME medical necessity considerations

Guideline-based clinical indicators that support consideration of airway clearance devices

Neuromuscular disease with impaired cough: Consider assisted cough technologies and aggressive airway clearance for patients whose history suggests difficulty clearing secretions or who have cough peak flow < 270 L/min and/or maximal expiratory pressures < 60 cm H2O<270 L/min (PCF); <60 cm H2O (MEP)

ATS consensus statement (Finder et al., 2004) and BTS guidance support these indicators

Perioperative high-risk surgical patients: High-risk thoracic, upper abdominal, or aortic surgical patients may derive benefit from OLE therapy to reduce postoperative pulmonary complications per a prospective multicenter study, but further confirmatory trials are required

Huynh et al. (2019) findings summarized in policy

Documentation Required

Include device specifics, imaging/diagnostics, comorbidities, and proper-use evidence in records

When submitting a request, include the specific device requested, whether the request is for an initial trial or ongoing use, recent relevant imaging and diagnostic testing, comorbidities, and for continuation beyond the two-month trial, provide evidence of proper device use.

Clearly state device model and trial vs ongoing status
Attach recent imaging/diagnostic results and list comorbidities
For continuation, include evidence of proper use during the 2-month trial

OLE — definition (alternate)

Alternate OLE definitionOscillation and Lung Expansion (OLE): combination therapy using continuous high-frequency oscillation plus continuous PEP and nebulized medications aimed at reducing postoperative pulmonary complications and improving lung expansion

Study contextOLE studied in multicenter nonrandomized prospective perioperative research showing reduced postoperative pulmonary complications and resource use, but authors called for controlled trials

Coverage implicationDespite some positive perioperative findings, OLE devices are still considered unproven and not medically necessary for routine use